WINNIPEG, Manitoba - (October 9, 2003). Medicure
Inc. (TSX:MPH), Medicure Inc. (TSX:MPH), a cardiovascular drug discovery
and development company, is pleased to announce that it will conduct
a live web cast of its Annual General and Special Meeting of Shareholders
on Wednesday, October 15, 2003 at 11 am Eastern Time. Interested
parties may listen to the enhanced audio web cast by visiting the
Medicure web site at www.medicureinc.com or CCN Matthews website
at www.ccnmatthews.com beginning at 11 am ET on October 15.
About Medicure
Inc.
Medicure
Inc is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine. The Company's lead drug,
MC-1, is focused on the prevention and treatment of ischemia, ischemic
reperfusion injury, and stroke. The cardiovascular and stroke market
is the largest pharmaceutical sector with annual global sales of
over US $70 billion.
The Company's second product candidate, MC-4232, is being targeted
for the treatment of hypertension, a common disorder in which blood
pressure remains abnormally high. Approximately 73% of the more
than 50 million adult Americans who have hypertension, are not adequately
treated.
Medicure also has a medicinal chemistry based Drug Discovery program
focused on discovery and advancement of novel small molecule, anti-ischemics
and anti-thrombotics towards human clinical studies.
This news release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Don Bain
Director of Investor & Public Relations
